Original site: www.cdc.gov/mmwr/preview/mmwrhtml/mm5743a5.htm RestoredCDC.org is an independent project and is not affiliated with, endorsed by, or associated with the Centers for Disease Control and Prevention (CDC) or any government entity. The CDC provides information free of change at CDC.gov. Note the following: 1) Due to archival on January 6, 2025, no information on recent outbreaks is available. 2) Videos have not been restored. 3) Use of this site implies acceptance of this disclaimer.
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Revised Product Labels for Pediatric Over-the-Counter Cough and
Cold Medicines
October 7, 2008, the Consumer Healthcare Products Association announced that the leading manufacturers of
pediatric over-the-counter cough and cold medicines would voluntarily modify the labels on these products to state that they
should not be used in children aged <4 years.*
Previous product labels stated that these medicines should not be used in children aged <2 years. Existing products
with these labels will not be removed immediately from store shelves but are expected to be replaced eventually with newly
labeled products. Health-care providers should be aware of the new labels and should alert parents and caregivers to this change.
Serious injuries and deaths have been reported among infants and children who received over-the-counter cough and
cold medicines, but most adverse events resulted from overdoses or unsupervised ingestions
(1--3). To promote child safety, the Food and Drug Administration and CDC have developed materials to educate parents, health-care providers, and
consumers about how and when these products can be used safely. Additional information is available at
http://www.fda.gov/bbs/topics/news/2008/new01899.html.
References
Food and Drug Administration. Cold, cough, allergy, bronchodilator, antiasthmatic drug products for over-the-counter human use.
Memorandum from the Nonprescription Drug Advisory Committee meeting, October 18--19, 2007. Available at
http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4323b1-02-fda.pdf.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
